Can common diabetes drugs shield the heart? AI and Real-World data seek answers
NCT ID NCT07770737
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This observational study looks at whether two classes of diabetes medications—SGLT2 inhibitors and GLP-1 receptor agonists—help protect the heart in Korean adults with type 2 diabetes. Researchers will analyze health records from multiple hospitals to compare heart attack, stroke, and heart failure rates among patients taking these drugs. In a smaller phase, about 100 patients starting an SGLT2 inhibitor will undergo heart imaging, AI-based ECG, and blood tests to see if early changes in heart function can be detected. The study does not assign any treatments; patients receive their usual care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SGLT2 inhibitors and GLP-1 receptor agonists (medications for type 2 diabetes)
- What this could lead to
- If successful, this could clarify which diabetes medications best protect the heart, potentially guiding treatment choices to reduce heart attacks, strokes, and heart failure in people with type 2 diabetes.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. Results may be influenced by other factors, and the small prospective phase may not be generalizable to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hallym University Dongtan Sacred Heart Hospital
Hwaseong-si, Gyeonggi-do, 18450, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can remote glucose monitoring tame type 2 diabetes in underserved communities?
- Fat cell 'Messages' may harm blood vessels — can exercise or surgery stop them?
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Could a simple health chat slash heart disease and cancer risk?
- One scan, many answers: can a new CT predict heart risks after stenting?